Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-19

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stage 1 proposed study will provide evidence to support the use of twice-daily dose 50mg DTG in children (20-35kgs) co-treated with RIF.

Note: An amendment has been added to include children from 3kgs and a dose of 10mg dispersible DTG

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

NCT05069688

Pediatric HIV Infection Tuberculosis Infection

RECRUITING PHASE1

Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)

NCT01637558

Tuberculosis HIV

COMPLETED PHASE4

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

NCT04166474

Hiv Tuberculosis

COMPLETED PHASE4

Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana

NCT01687504

Tuberculosis HIV

UNKNOWN

Rifampin and Efavirenz Interactions in Older Children

NCT01704144

HIV Tuberculosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single centre, open-label, non-randomised, prospective study evaluating the steady-state pharmacokinetics of twice-daily dose DTG administered during concurrent RIF treatment and assessing safety and tolerance in HIV-TB co-infected children weighing 20 to 35 kg.

DTG will be administered as a twice-daily dose 50mg tablet formulation both before starting and after completion of the standard six-month RIF-based anti-TB treatment. The NRTI background and anti-TB drugs will be prescribed following the national weight band dosing guidelines.

Those initially diagnosed with TB are likely to be sicker, and the recommendation is to start anti-TB treatment first and follow with ART two weeks later.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis Hiv

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Pharmacokinetic evaluation of DTG in children receiving Rifampicin containing TB treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Twice Daily DTG

Twice daily Dolutegravir (50mg) with Rifampicin containing TB treatment / Twice daily Dolutegravir (10mg) dispersible

Group Type OTHER

Dolutegravir 50 MG

Intervention Type DRUG

Twice daily dolutegravir with rifampicin containing TB treatment

Dolutegravir 10 MG

Intervention Type DRUG

Twice daily dolutegravir with rifampicin containing TB treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dolutegravir 50 MG

Twice daily dolutegravir with rifampicin containing TB treatment

Intervention Type DRUG

Dolutegravir 10 MG

Twice daily dolutegravir with rifampicin containing TB treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children \<18 years with confirmed HIV-1 infection weighing 20-35kg ART-naive or experienced, with plans to use DTG for HIV treatment
* Diagnosis of TB disease with clinician initiating rifampicin-containing first-line therapy
* Parents/legal guardians/caregivers and children give informed written consent (or assent, where applicable) to be in the study
* Girls who have reached menses must have a negative pregnancy test at screening and be willing to adhere to two effective methods of contraception (barrier and a non-barrier form of contraception during the study, starting at least 14 days prior to enrolment) if sexually active. The parents/caregivers will be counselled together with the child if the child tests positive in order to reduce any social harm which may arise.

Exclusion Criteria

* History or presence of known allergy or contraindications to DTG
* Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥2xULN
* Severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones)
* Pregnancy or breastfeeding
* A concurrent illness that could influence drug PK, i.e. severe diarrhoea, vomiting, renal or liver disease
* Treatment with concomitant medications known to have interactions with DTG
* Participants that are eligible for the study but refuse to give consent and/or assent

Minimum Eligible Age

23 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No